Shilpa Pharma Secures CEP Certification for Nifedipine API

Shilpa Pharma Lifesciences Secures CEP for Nifedipine API from EDQM

Shilpa Pharma Lifesciences Limited, a wholly-owned subsidiary of Shilpa Medicare Limited, has been granted a Certificate of Suitability (CEP) by the European Directorate for the Quality of Medicines & Healthcare (EDQM) for its Active Pharmaceutical Ingredient (API), Nifedipine.

• A CEP certifies that the API complies with European Pharmacopoeia (Ph. Eur.) standards, validating its quality and suitability for medicinal products in Europe.
• This achievement highlights Shilpa Pharma’s expertise in producing APIs that meet global quality benchmarks.

Nifedipine, a calcium-channel blocker, is widely used to manage hypertension and angina by relaxing blood vessels, reducing cardiac workload, and improving oxygen supply to the heart.

The recognition reinforces Shilpa Pharma’s commitment to high-quality API development and global market competitiveness.